Stifel analyst Paul Matteis reiterated a Buy rating and $58.00 price target on Sage Therapeutics (NASDAQ: SAGE), following the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE